Oruka Therapeutics, Inc. (ORKA) Debt Components
- 2023-12-31: Debt, Long-term and Short-term, Combined AmountUSD $0.00; Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31)USD (m).
- 2022-12-31: Debt, Long-term and Short-term, Combined AmountUSD $0.00; Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31)USD (m).
- 2021-12-31: Debt, Long-term and Short-term, Combined AmountUSD $0.00; Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31)USD (m).
- 2020-12-31: Debt, Long-term and Short-term, Combined AmountUSD $0.00; Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31)USD (m).
Oruka Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt, Long-term and Short-term, Combined Amount USD | Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31) USD |
|---|---|---|
| 2023-12-31 | $0.00 | (m) |
| 2022-12-31 | $0.00 | (m) |
| 2021-12-31 | $0.00 | (m) |
| 2020-12-31 | $0.00 | (m) |
| 2019-12-31 | $0.00 | (m) |
| 2018-12-31 | $0.00 | (m) |
| 2017-12-31 | $0.00 | (m) |
| 2016-12-31 | $0.00 | (m) |
| 2015-12-31 | $0.00 | (m) |
| 2011-06-30 | (m) | 114 month · $163.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |